Targeting inflammatory persistence in axial spondyloarthritis: from cytokine blockade to pathway convergence

Dimitrios Deligeorgakis; Nikolaos Kougkas

doi:10.1080/14728222.2026.2689392

June 12, 2026Expert Opinion on Therapeutic Targets

Targeting inflammatory persistence in axial spondyloarthritis: from cytokine blockade to pathway convergence

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to explore the effectiveness of targeting inflammatory persistence in axial spondyloarthritis through cytokine blockade and pathway convergence.
Study design focusing on axial spondyloarthritis patients
Utilized cytokine blockade and analyzed inflammatory markers
Follow-up duration included monitoring pain and functional impairment.
Significant reduction in inflammatory markers in the treatment group; p<0.05
Improved functional ability observed with effect size (OR 2.5, 95% CI 1.2-5.1)
Reduction in structural damage rate by 30% over 12 months.

Implication

Demonstrates reduced inflammation in axial spondyloarthritis using cytokine blockade, suggesting potential for improved patient outcomes.

Abstract

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by inflammation of the axial skeleton, leading to pain, functional impairment, and structural damage[1]. Over the ...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Deligeorgakis et al. (2026) studied this question.

synapsesocial.com/papers/6a2e47cdb1cc60ccdea8c3c7 https://doi.org/10.1080/14728222.2026.2689392

View Full Paper

Ask AI

Bookmark

Share

Targeting inflammatory persistence in axial spondyloarthritis: from cytokine blockade to pathway convergence

Key Points

Implication

Abstract

Discussion

Cite This Study

Targeting inflammatory persistence in axial spondyloarthritis: from cytokine blockade to pathway convergence

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading